Skip to content
Cross Border Deals 2018

PwC’s Year-End Life Sciences Deals Insights

Despite a strong desire for companies to be active in M&A and continued acquisition and divestiture evaluation, many buyers were kept from executing on their inorganic growth agendas due to inflated valuations (related to bid/ask differences), leadership changes (allowing time for new strategy to be…

Read More